Baxter International Fourth Quarter 2010 Financial Results Conference Call

DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International (NYSE:BAX) will host a quarterly conference call to discuss its fourth quarter 2010 financial results on Thursday, January 27, 2011, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). To access the call, please dial 866-261-7280 (domestic) or 703-639-1228 (international). Please dial into the call at least ten minutes prior to the start of the call for the operator to connect you.

This call is being webcast by Thomson/CCBN and can be accessed at Baxter’s Web site at http://www.baxter.com/. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter’s permission.

The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.

Baxter International Inc. develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.



CONTACT:

Baxter International Inc.
Investor Relations:
Mary Kay Ladone, +1-847-948-3371
[email protected]
or
Clare Trachtman, +1-847-948-3085
[email protected]

KEYWORDS:   United States  North America  Illinois

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Medical Devices  Pharmaceutical  General Health

MEDIA:

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.